Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ONCOGENEX PHARMACEUTICALS Inc OGXI

Healthcare Biotechnology
"OncoGenex Pharmaceuticals Inc is a biopharmaceutical company focused on the development of cancer treatment resistance. It has developed Apatorsen to block the production of heat shock protein 27, or Hsp27, that promotes treatment resistance in cancer."

Recent & Breaking News (NDAQ:OGXI)

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conference

Canada NewsWire March 28, 2013

OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012

PR Newswire March 7, 2013

OncoGenex to Webcast Update on Clinical Development Program and Discussion of Fourth Quarter and Full Year 2012 Financial Results on Thursday, March 7, 2013

Canada NewsWire February 28, 2013

OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer

PR Newswire February 12, 2013

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences

Canada NewsWire February 5, 2013

Perfect Trade Setups, How to Play UNXL, AMRS, FORD and OGXI

Marketwired January 2, 2013